Tislelizumab: all 398 studies that test it
Page 4 of 4. Open to participants first (214), then studies with results posted, then the rest; newest registration first within each.
- HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCCStatus unknownNCT05582278Phase 2
- Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular CarcinomaWithdrawnNCT05564338Phase 3
- Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 ResectionActive, not recruitingNCT05546619Not applicable
- Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of RecurrenceStatus unknownNCT05545124Phase 2
- Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)Active, not recruitingNCT05520619Phase 2
- Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell CarcinomaCompletedNCT05517330Phase 2
- A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant TumorsCompletedNCT05516914Phase 1/2
- Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCCCompletedNCT05516589Phase 2
- Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid TumorsCompletedNCT05508100Phase 1
- Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete RemissionActive, not recruitingNCT05502250Phase 2
- Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid TumorsTerminatedNCT05494762Phase 1
- Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCCStatus unknownNCT05469061Phase 2
- Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid TumorsStatus unknownNCT05441046Phase 1
- Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard TherapyActive, not recruitingNCT05435313Phase 2
- Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center StudyStatus unknownNCT05418309Phase 2
- Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver MetastasisStatus unknownNCT05406466Phase 2
- The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCCActive, not recruitingNCT05343325Phase 2
- SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung CancerActive, not recruitingNCT05319574Phase 2
- TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal CancerStatus unknownNCT05314101Phase 2
- Tislelizumab and Radiotherapy for Recurrent Cervical CancerStatus unknownNCT05310383Phase 2
- Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant AscitesStatus unknownNCT05303844Phase 1
- Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)Status unknownNCT05277675Not applicable
- Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung CancerStatus unknownNCT05273814Phase 1
- Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella TrialStatus unknownNCT05270889Phase 2
- Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)Active, not recruitingNCT05253118Phase 2
- A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical CancerStatus unknownNCT05247619Phase 2
- ChemoRadiation And Tislelizumab for Esophageal/EGJ CancerWithdrawnNCT05245760Phase 2
- Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLCStatus unknownNCT05244837Phase 2
- Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown PrimaryStatus unknownNCT05241132Phase 2
- A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid TumorsActive, not recruitingNCT05238883Phase 1
- A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLCActive, not recruitingNCT05228496Phase 2
- Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric CancerCompletedNCT05223088Phase 2
- Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal CarcinomaActive, not recruitingNCT05211232Phase 3
- Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain MetastasesStatus unknownNCT05207904Phase 2
- Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic SubtypeTerminatedNCT05207709Phase 3
- Tislelizumab as Cross-line Treatment for Advanced NSCLCStatus unknownNCT05192681Phase 2
- Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCCActive, not recruitingNCT05189730Phase 2
- First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate CancerActive, not recruitingNCT05189457Phase 2
- Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLCTerminatedNCT05176925Phase 2
- HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors StudyActive, not recruitingNCT05167071Phase 1
- Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal CancerStatus unknownNCT05160727Phase 2
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Phase 3
- Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular CarcinomaStatus unknownNCT05131698Early Phase 1
- Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic MelanomaStatus unknownNCT05104801Phase 2
- Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal CarcinomaStatus unknownNCT05092217Phase 2
- Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal CancerCompletedNCT05086627Phase 2
- Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell LymphomaCompletedNCT05058755Not applicable
- Tislelizumab in Addition to BACE in Patients with NSCLCCompletedNCT05058560Phase 2
- Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian CancerCompletedNCT05044871Phase 2
- Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.Status unknownNCT05036798Phase 2
- Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell CarcinomaStatus unknownNCT05024266Phase 2
- Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical CarcinomaStatus unknownNCT05013268Phase 1
- ALPPS Combined With Tislelizumab in Liver MalignancyStatus unknownNCT04996446Phase 2
- Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune ScoreStatus unknownNCT04989855Phase 2
- A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative ResectionStatus unknownNCT04981665Phase 2
- Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 MutationsStatus unknownNCT04969029Phase 2
- The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)Status unknownNCT04948034Phase 2
- L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant MelanomaTerminatedNCT04924413Phase 2
- Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)Status unknownNCT04922047Phase 1/2
- Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT04921995Phase 2
- Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II StudyStatus unknownNCT04913571Phase 2
- Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder CancerStatus unknownNCT04909775Phase 2
- Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial CancerTerminatedNCT04906382Early Phase 1
- Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic CancerStatus unknownNCT04902261Phase 2
- Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell LymphomaStatus unknownNCT04899414Phase 2
- Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJCStatus unknownNCT04890392Phase 2
- Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung CancerStatus unknownNCT04865705Phase 2
- Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTTStatus unknownNCT04850157Phase 2
- A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL StudyStatus unknownNCT04814069Phase 2
- Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing TumorsActive, not recruitingNCT04802876Phase 2
- Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative RecurrenceStatus unknownNCT04782804Phase 1/2
- Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal CancerStatus unknownNCT04777162Phase 2
- Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal CancerActive, not recruitingNCT04776590Phase 2
- Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely ResectableStatus unknownNCT04730232Phase 2
- Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder CarcinomaStatus unknownNCT04730219Phase 2
- Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract CancerActive, not recruitingNCT04727996Phase 2
- Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCLStatus unknownNCT04705129Phase 2
- Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial CarcinomaCompletedNCT04672330Phase 2
- LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT04666688Phase 1/2
- Tislelizumab in Combination With TACE in Advanced Hepatocellular CarcinomaStatus unknownNCT04652492Phase 2
- Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line ChemotherapyStatus unknownNCT04620837Phase 2
- Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial CarcinomaCompletedNCT04570410Phase 2
- Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive ChemotherapyStatus unknownNCT04541277Phase 2
- A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell LymphomaCompletedNCT04539444Phase 2
- Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLCCompletedNCT04507217Phase 2
- Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast CancerStatus unknownNCT04498793Phase 2
- Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin LymphomaTerminatedNCT04486391Phase 3
- A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell LymphomaTerminatedNCT04425070Phase 1/2
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin MalignancyActive, not recruitingNCT04387084Phase 1
- Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04379635Phase 3
- Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung AdenocarcinomaCompletedNCT04310943Phase 2
- A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal CancerTerminatedNCT04294160Phase 1
- Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT04215978Phase 1
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesCompletedNCT04164199Phase 3
- Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass NodulesCompletedNCT04047186Phase 2
- Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial CarcinomaActive, not recruitingNCT03967977Phase 3
- ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung CancerCompletedNCT03732664Phase 1
- Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung CancerCompletedNCT03432598Phase 2